PRECISION BIOSCIENCES INC (DTIL): Nasdaq/NYSE listing notice — Precision BioSciences receives Nasdaq deficiency letter for bid price below $1.00

PRECISION BIOSCIENCES INC

Nasdaq notified on April 24, 2023 that DTIL common stock closed below $1.00 for 30 consecutive business days.
Company has 180 days, until October 23, 2023, to regain compliance by having bid price ≥$1.00 for 10 consecutive days.
If not compliant by deadline, DTIL may request transfer to Nasdaq Capital Market and obtain an additional 180-day period.
Company may consider a reverse stock split to cure the deficiency, but no assurance of regaining compliance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

PRECISION BIOSCIENCES INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

April 24, 2023, Precision BioSciences, Inc. (the “Company”) received a letter (the “Nasdaq Staff Deficiency Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The Nasdaq Staff Deficiency Letter has no immediate effect on the listing or trading of the Co

View on SEC.gov

Browse all listing & compliance notices →

PRECISION BIOSCIENCES INC filing history →

Source: SEC EDGAR

accession 0000950170-23-015876

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.